Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Abstract 


Pharmacological inhibition of the extracellular zinc metalloprotease A Disintegrin-like And Metalloprotease domain with Thrombospondin type I motifs 5 (ADAMTS5) has been proposed as a treatment for osteoarthritis (OA), a degenerative disease characterized by cartilage loss. More recently, ADAMTS5 has been implicated in ovarian cancer (OC), due to its essential role in promoting cell migration and association with poor prognosis. ADAMTS5 major substrates are the proteoglycans aggrecan and versican, which support the structural integrity of the cartilage and the tumor microenvironment. We have recently described a non-chelating arylsulfonamide glycoconjugate, compound 4b, as a selective ADAMTS5 inhibitor, and shown its effectiveness in an OC 3D model. Here, we modified the structure of 4b to improve its biological activity. We showed that, while 4b induces cytotoxicity in several cell lines as well as in porcine and human cartilage explants, its derivative 2 was tolerated at high micromolar concentrations and effective in inhibiting aggrecan degradation in human ex vivo OA explants and reducing directional OC cell migration and pseudopod elongation. In silico analyses provided a rationale behind the different biological activities of the two compounds. These findings highlight the potential of non-chelating glycoconjugated arylsulfonamides to treat pathologies characterized by excessive ADAMTS5 activity.

Free full text 


loading

Citations & impact 


This article has not been cited yet.

Data 


Data behind the article

This data has been text mined from the article, or deposited into data resources.

Similar Articles 


To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.


    Funding 


    Funders who supported this work.

    Breast Cancer Now (1)

    British Heart Foundation (1)

    Cancer Research UK (1)

    • Grant ID: C52879/A29144

    Medical Research Council (1)

    • Grant ID: MR/X009203/1

    The Humane Research Trust

      Università di Pisa (1)

      • Grant ID: PRA_2022_19

      Versus Arthritis (1)

      Wellcome Trust (1)

      • Grant ID: WT093134AIA

      Yorkshire Cancer Research (1)

      • Grant ID: YCRSPF\2024\100093

      • Annotations
        In full text (602)

      • Save

      • Open PDF

      • Claim to ORCID